Detail
| LncRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 Sequence |
| Ensembl | ENSG00000240498 |
| RefSeq | NR_003529 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | bladder urothelial cancer |
| ICD-0-3 | M8120/3 |
| Methods | qPCR, Western blot, etc. |
| Sample | BUC tissues, cell lines (SV-HUC-1, J82, T24) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA CDKN2B-AS is high-expressed in BUC and related to low Gemcitabine sensitivity of BUC. CDKN2B-AS inhibited Gemcitabine sensitivity through Wnt signaling pathway in BUC. |
| Pubmed ID | 29937935 |
| Year | 2018 |
| Title | Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. |
| External Links |
| Links for ANRIL | GenBank HGNC lncrnadb Noncode |
| Links for bladder urothelial cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.